My prediction is:
1. All of 2015, institutions will continue to accumulate; upto 75% of the shares outstanding
2. Stock will remain between $2 and $4 till Oct-Dec 2016
3. Oct-Dec APD 334 phase II results will be released with extraordinary results
4. MM-Institiutions will hype inflate price to $40-45 p/s
I am long ARNA
Just a predection.....
NO, I DIDN'T THINK YOU WOULD.
Just said Stockvadar using false ID to look like StockvadEr. Short BS tactics to get retail longs to sell, absolutely ridiculous.
Everyone who's been in the market knows this is a complete fallacy!!! If this where true of ARNA, how is it that the institutions are buying up all the shares and the price is declining. SIMPLE FACT THEY SET THE PRICE NOT THE SUPPLY OR THE DEMAND. Retail investors owned the majority of the shares, instititutions wanted those shares on the cheap. So they dictate the price... LOWER THE PRICE THEN THEY START ACCUMULATING THE SHARES.....WHEN ARNA WAS APPROVED BY THE FDA INSTITUTIONS OWN less than 25% NOW THEY OWN ALMOST 60%.....EXPLAIN THIS ONE....
Such concerns are well founded. Traditionally, being overweight in India was seen as a sign that your family was prosperous. But as the country’s economy has boomed, consumers have developed a taste for Western-style fast food. In July, a 225-year-old traditional sweet shop in Delhi was forced to close its doors as the taste for chocolate outstrips the demand for time-honored treats. As a result, the South Asian nation’s obesity rate has soared. A study published last year in the medical journal Lancet revealed that one in five Indians is obese, and as many as 60 percent of people who live in India’s cities are estimated to be obese.
The committee recommended that the shops be prohibited from selling unhealthy items to kids who are wearing uniforms—it’s easy to identify pupils in India, because nearly all primary and secondary institutions require students to wear school-specific ensembles. The prohibition would include brick-and-mortar shops and restaurants as well as food carts that can be pushed from place to place.
LIKE CLOCKWORK, can't wait till Monday to see what happens.
times there revenue. They use the BS argument to justify the MM Manipulation of the stock so large institutions can buy your shares for the cheap. This is there play book for small cap biotechs.
Drug gets positive results or approved; run the price up a bit, then naked short as long as it takes to recover all the while continue to buy on the way down until they own 90+ percent of the stock. Then inflate the price to an astronomical number.
Examples: JAZZ, VRTX, KERX, DNDN, ICPT, RCPT, etc.., etc....
As you can see that was a buy order..and still didn't move the price that much higher, absolutely sickening manipulation...
POSTER IS VERY LONG ARNA
This is the reason you see the SPOOFING of sell 100, 100, 200, 100, 500, then buy 1000. It's evident on the NASDAQ website, look at the real time trades.
The SEC is powerless against it unless the company sues and ID's the naked short sellers and the spoofers.
BOUGHT and PAID FOR......
"The Securities and Exchange Commission suffered a fresh setback to its controversial use of in-house judges, when a Manhattan federal judge ruled Wednesday the tribunal was likely unconstitutional. U.S. District Judge Richard Berman is the second federal judge to find the SEC didn't appoint its five administrative law judges correctly, adding to pressure on the agency to reform the system. Judge Berman agreed Wednesday to temporarily halt an SEC administrative action against Barbara Duka, a former Standard & Poor’s Ratings Services executive. Ms. Duka, who denies the SEC’s civil allegations of fraud, sued the agency over its decision to try her before its own judges. [...] In his ruling, Judge Berman said that if the SEC were allowed to go ahead with its in-house case against Ms. Duka, she would “be forced into an unconstitutional proceeding.” The SEC in-house judges involved in her case were “not appropriately appointed,” the Manhattan court found. The SEC is battling several other federal court challenges, which are fueling criticism from defense lawyers and business groups that the system is unfair, particularly for more complex cases. The criticism concerns a crucial tool in the SEC’s enforcement armory. The agency has been sending more cases to its own judges, in part because of new powers granted by the Dodd-Frank financial law of 2010. The SEC sent 82% of its cases to its in-house judges in the six months through March, according to Cornerstone Research, compared with less than half in the fiscal year ended September 2005."
Of course the judge is from Manhattan!!!!! Who do you thinks paying him........BOUGHT AND PAID FOR!!!!
This is sickening....That the SEC let's this go!!!!!
Spencer, First, you said the stock price was over valued! The question I ask again, who puts the value on a stock? Sorry, that was a rhetorical question-the market makers do. Who do the MM work for? Again, rhetorical...That's right the institutions. Spencer, I've played in biotech for the last ten years, and this playbook that the institutions use is sickening! I truly write to educate the retail investor, you on the other will feed them slices of facts based on information that's already readily available to all. What readers expect is nuggets of information that will make them better informed when investing or trading. Your, articles would be much more beneficial if you included market dynamics aside from weekly sales numbers, and tv ad numbers. What is the overall strategy of the big boys playing this stock? (Compare, OREX, VVUS, ARNA-strategic initiatives, pipeline growth, political decisions effecting the company/companies, outside threats, M&A potential etc. So, what I'm saying spencer is write something with substance that readers want to read. I see your articles and I skip to the end to see what logical comments are being rendered below, because I already know what's in the article from the headline. (I listented to the CC, I get the IMS numbers, I get the TV ad information-regurtitation of the facts). I want an orginial thought! "These are not the Droids you're looking for"
have $216 Million in cash, $1 Billion in NOLs, 1 FDA approved drug, 5+ potential product candidates, you tell me how much we're worth?
Something just doesn't add up, shorts are saying institutions are jumping ship but NASDAQ 06/30/15 filings say something completely different......these are shares not dollars.......
New Positions 21 24,319,038
Sold Out Positions 22 4,398,402
I'm long ARNA
In the development of bowel inflammation, leukocyte (white blood cells or WBCs) are recruited into the inflamed intestine as the WBCs roll along and attach to receptors on the endothelium (the lining of the interior surface of blood vessels). APD334 modulates lymphocyte (one of the 3 types of WBCs) trafficking from lymph nodes to the peripheral blood. Trapping lymphocytes in lymph nodes means fewer immune cells are available in the circulating blood for recruitment. Approved drugs Tysabri from Biogen (NASDAQ:BIIB) and Entyvio from Takeda (OTCPK:TKPHF) block the adhesion molecules between the receptors of WBCs and endothelial cells. Tysabri is effective in CD and multiple sclerosis, but clinical use is limited due to the risk of developing progressive multifocal leukoencephalopathy, a fatal viral brain disease. The risk arises because Tysabri affects WBC recruitment of in all organs, including the central nervous system, while Entyvio selectively blocks recruitment of immune cells to the GI tract. Entyvio is approved in CD and UC.
It takes a whole lot of competance to invest in a company; another short Moron! Look if that's the best retort you have, no wonder you're desperate!!!!